生物技术公司Recursion Pharmaceuticals, Inc.（股票代码：RXRX）今日盘中股价大跌5%，主要原因是公司公布的季度业绩未达市场预期。
根据公司最新发布的财报显示，截至6月30日的季度，Recursion Pharmaceuticals调整后每股亏损41美分，低于分析师平均预期的每股亏损35美分。虽然公司营收同比增长33.3%达到1922万美元，超过分析师预期的1543万美元，但巨额亏损仍令投资者感到失望。该季度公司净亏损高达1.719亿美元。
Recursion Pharmaceuticals是一家临床阶段的生物技术公司，致力于通过整合生物学、化学、自动化、数据科学和工程学的技术创新来解码生物学，以改善患者生活并推动药物发现产业化。尽管公司在技术创新方面备受关注，但持续的亏损状况引发了市场对其财务可持续性的担忧。值得注意的是，尽管今日股价下跌，分析师对该公司的12个月目标价中位数仍为6.50美元，较当前股价有一定上涨空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.